Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, faced serious malfunctions after its launch in Canada, including under-infusion and over-infusion of medications [4][5]. - The company previously claimed that the Novum LVP had advanced safety features and that the Canadian rollout would help resolve any issues [5]. Group 3: Stock Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, leading to a stock price drop of $6.29 per share, or over 22%, from $28.05 to $21.76 [6].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018 [3]. - Investors have until December 23, 2025, to request to be appointed to lead the case [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations of Fraud - During the relevant period, James Hardie claimed strong performance in its North American fiber cement segment, asserting "inherent strength" and "underlying momentum" in its strategy [5]. - The complaint alleges that the reported sales were due to inventory loading by channel partners rather than sustainable customer demand, indicating potential fraudulent channel stuffing [5]. Group 4: Stock Performance - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers [6]. - Following this announcement, the stock price plummeted by $9.79 per share, a decrease of over 34%, from $28.43 to $18.64 per share [6].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of Avidity Biosciences, Inc. to Novartis for $72.00 per share in cash, raising concerns about whether shareholders are receiving adequate value for their shares [1][3]. Group 1: Investigation Details - The investigation focuses on whether Avidity and its board violated federal securities laws and fiduciary duties by not obtaining the best possible consideration for shareholders [3]. - Key concerns include whether Novartis is underpaying for Avidity and whether all material information necessary for shareholders to assess the merger has been disclosed [3]. Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other forms of relief related to the proposed transaction [4]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [4].

Core Viewpoint - Molina Healthcare, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims centered around undisclosed adverse financial conditions and misleading guidance during the class period from February 5, 2025, to July 23, 2025 [1][3]. Summary by Sections Class Action Details - The class action lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and it allows purchasers of Molina Healthcare securities during the specified class period to seek lead plaintiff status by December 2, 2025 [1][2]. Allegations Against Molina Healthcare - The lawsuit alleges that Molina Healthcare failed to disclose critical information regarding its medical cost trend assumptions, a dislocation between premium rates and medical costs, and that its near-term growth relied on reduced utilization of various health services [3]. - It is claimed that Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced due to these undisclosed issues [3]. Financial Performance and Stock Impact - On July 7, 2025, Molina Healthcare reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines, leading to a 10.2% cut in earnings guidance [4]. - Following the financial results announcement on July 23, 2025, Molina reported a GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and further reduced its full-year 2025 earnings guidance to no less than $19.00 per diluted share, resulting in a nearly 17% drop in stock price [5].

Core Insights - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving F5, Inc. (NASDAQ: FFIV) regarding false or misleading statements made by the company and its executives [1][2] - F5 disclosed on October 15, 2025, that a nation-state threat actor gained unauthorized access to its systems, leading to the exfiltration of files, including portions of the BIG-IP source code and information on undisclosed vulnerabilities [3] Company Overview - F5 provides multi-cloud application security and delivery solutions [2] Investigation Details - The investigation focuses on whether F5 and its executives failed to disclose material information to investors, which may have contributed to a decline in the company's stock price following the security breach revelation [1][3]

Core Viewpoint - The James Hardie Industries plc is facing a class action lawsuit alleging securities fraud due to misleading statements about its North America Fiber Cement segment's performance during a period of inventory destocking [1][4][5]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc" and is filed in the Northern District of Illinois [1]. - Investors who purchased James Hardie common stock between May 20, 2025, and August 18, 2025, have until December 23, 2025, to seek lead plaintiff status [1][6]. - The lawsuit alleges that James Hardie executives made false assurances about the strength of their business segment despite evidence of declining sales and inventory issues [4][5]. Group 2: Allegations Against James Hardie - The lawsuit claims that starting in April and early May 2025, there was evidence of customer destocking, which was not disclosed to investors [4]. - On August 19, 2025, James Hardie reported a 12% decline in sales in the North America Fiber Cement segment, which led to a stock price drop of over 34% [5]. Group 3: Company Background - James Hardie Industries designs and manufactures a variety of fiber cement building products, with manufacturing facilities in the United States and Australia [3].

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Baxter International Inc. (NYSE: BAX)?Did you purchase your shares between February 23, 2022 and July 30, 2025, inclusive?Did you lose money in your investment in Baxter International Inc.?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors of an upcoming deadline invo ...

Core Viewpoint - A securities fraud class action lawsuit has been initiated against MoonLake Immunotherapeutics, alleging misrepresentations regarding its drug candidate sonelokimab [3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired MoonLake common stock between March 10, 2024, and September 29, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [3]. Group 2: Company Information - MoonLake's sole drug candidate, sonelokimab, was promoted as superior to competing monoclonal antibody drugs, which is central to the allegations in the lawsuit [4]. - Investors are reminded of a deadline to file as lead plaintiff by December 15, 2025, which allows them to represent the class in the litigation [5]. Group 3: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless there is a recovery [5][6]. - The firm has a history of recovering over $3.5 billion for clients and has been recognized multiple times for its litigation success [6].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Cadence Bank to Huntington Bancshares Incorporated for Cadence shareholders [1][3]. Group 1: Transaction Details - Huntington Bancshares will issue 2.475 shares of common stock for each outstanding share of Cadence common stock as part of the transaction [1]. Group 2: Legal Investigation - The investigation focuses on whether Cadence and its board violated federal securities laws and fiduciary duties by not securing the best possible consideration for shareholders, potentially underpaying for Cadence, and failing to disclose all material information necessary for shareholders to assess the merger [3]. - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [4]. Group 3: Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [5].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between Huntington Bancshares Incorporated and Cadence Bank for Huntington shareholders [1][2]. Group 1: Investigation Details - The investigation focuses on whether Huntington and its board violated federal securities laws and breached fiduciary duties by not obtaining the best possible consideration for shareholders and failing to disclose all material information necessary for assessing the merger [2]. - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [3]. Group 2: Legal Representation - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4].